HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IDXX
IDEXX Laboratories, Inc.
IDXX's fundamentals are strong: it turned 28% of its revenue into free cash flow and free cash flow grew 35%. At 47x earnings, it's trading below its usual 54x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IDXX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
IDXX's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IDXX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 43x | $634 | -9.1% |
| Forward | 43x | $698 | — |
| Current | 47x | $698 | — |
| Fair | 53x | $793 | +14% |
| Expensive | 72x | $1,066 | +53% |
Historical ranges are pointers, not guarantees.
IDXX's PE is in its cheap range at 47x. If earnings grow as analysts expect, today's price would be 43x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IDXX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
IDXX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IDXX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $16.28 | +9.7% |
| Q3 2026 | $14.84 | +18% |
| Q2 2026 | $14.23 | +18% |
| Q1 2026 | $13.59 | +26% |
| Q4 2025 | $13.08 | +23% |
| Q3 2025 | $12.61 | +22% |
| Q2 2025 | $12.01 | +19% |
| Q1 2025 | $10.82 | +4.8% |
| Q4 2024 | $10.67 | +6.1% |
IDXX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IDXX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IDXX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +9.9% |
| Q2 2026 | $1.2B | +9.7% |
| Q1 2026 | $1.1B | +14% |
| Q4 2025 | $1.1B | +14% |
| Q3 2025 | $1.1B | +13% |
| Q2 2025 | $1.1B | +11% |
| Q1 2025 | $998.4M | +3.6% |
| Q4 2024 | $954.3M | +5.8% |
IDXX's revenue has grown year over year every quarter since late 2020: $1.2B last quarter, up 9.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +1 points |
| Q2 2026 | 35% | +1.4 points |
| Q1 2026 | 32% | +0.1 points |
| Q4 2025 | 29% | +1.5 points |
| Q3 2025 | 32% | +1 points |
| Q2 2025 | 34% | +7.3 points |
| Q1 2025 | 32% | +0.7 points |
| Q4 2024 | 27% | +0.2 points |
IDXX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
IDXX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $420.8M | +13% |
| Q2 2026 | $322.5M | +113% |
| Q1 2026 | $234.3M | +13% |
| Q4 2025 | $326.3M | +40% |
| Q3 2025 | $371.2M | +93% |
| Q2 2025 | $151.6M | -29% |
| Q1 2025 | $207.9M | +24% |
| Q4 2024 | $232.8M | +7.1% |
IDXX generated $1.3B in free cash flow over the past year, up 35% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IDXX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IDXX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -263K shares |
| 1 year | -2% | -1.6M shares |
| 3 years | -5.9% | -4.9M shares |
| 5 years | -8.6% | -7.5M shares |
| Available history | -9.7% | -8.5M shares |
IDXX has 79M diluted shares, down 2% from a year ago, with $1B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $112.2M |
| Q2 2026 | $346.8M |
| Q1 2026 | $351M |
| Q4 2025 | $237.8M |
| Q3 2025 | $240.2M |
| Q2 2025 | $338.1M |
| Q1 2025 | $400.9M |
| Q4 2024 | $246M |
IDXX spent $1B buying back its own shares over the past year, down 14% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IDXX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.4x | Very low |
| Q4 2024 | 0.3x | Very low |
IDXX's net debt is less than a year of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IDXX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.3 | Overbought |
| Stochastic | 72.0 | Neutral |
IDXX's weekly RSI is 72 (overbought) and its Stochastic is 72 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IDXX PE vs Healthcare Sector
| Metric | IDXX | Sector median | Relative |
|---|---|---|---|
| PE | 47x | 26x | 82% above |
| PE % | 28 | 29 | 1 pt below |
IDXX is trading at 47x earnings, a 82% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IDXX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $575.2 | 21% above |
| 20 week MA | $559.8 | 25% above |
| 50 week MA | $593.1 | 18% above |
| 100 week MA | $562.0 | 24% above |
| 200 week MA | $525.7 | 33% above |
IDXX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IDXX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $264.0 | $497.1 | +88% |
| 2021 | $497.1 | $645.0 | +30% |
| 2022 | $645.0 | $410.6 | -36% |
| 2023 | $410.6 | $555.1 | +35% |
| 2024 | $555.1 | $414.9 | -25% |
| 2025 | $414.9 | $688.5 | +66% |
| 2026 YTD | $688.5 | $698.0 | +1.4% |
IDXX has the edge over HIMS on returns for 2026, with the stronger performance.